mice remains to be determined.
If such properties are propagated, then this will suggest that different mutant human PrPs will have generated distinct strains of prions. The existence of prion strains has posed a conundrum as to the mechanism by which strain-specific characteristics are encrypted (23, 26) . Although differences in the size of protease-resistant fragments of PrP Sc have not been a general characteristic of prion strains (27), the hyper and drowsy strains of prions isolated from mink by serial passage in Syrian hamsters do differ with respect to the size of the PrP Sc molecules after limited proteolysis (28). But unlike the studies reported here, where prions were generated de novo in patients carrying the D178N or E200K mutations, the origin of the hyper and drowsy strains is obscure.
Our results provide a plausible mechanism for explaining diversity in a pathogen that lacks nucleic acid; the biological properties of prion strains seem to be encrypted in the conformation of PrP Sc . Because prion strains produce different disease phenotypes, such findings raise the possibility that deviations in the phenotypes of other degenerative disorders may also reflect conformational variants in pathologic proteins. Variations in the conformation of PrP Sc are reproduced through templating of the PrP Sc in the inoculum onto the substrate PrP C . Deciphering the molecular events by which the conformation of one protein is imparted to another and the mechanism responsible for the apparently high degree of fidelity associated with this process should be of considerable interest. Indeed, the foregoing data violate the widely and longheld idea that amino acid sequences are the sole determinants of the tertiary structures of biologically active proteins (29). 17. In contrast to Tg(HuPrP) mice, Tg(MHu2M) mice are susceptible to human prions (10) . When Tg(MHu2M)Prnp 0/0 mice were produced by crossing onto the PrP null background, a 20% reduction in incubation times was found (11). 18. P. Parchi et al., Ann. Neurol. 38, 21 (1995) . 19. L. Monari et al., Proc. Natl. Acad. Sci. U.S.A. 91, 2839 ; P. Parchi et al., Ann. Neurol. 39, 767 (1996 ). 20. G. Telling, N. Heye, S. B. Prusiner, unpublished data. 21. A. Taraboulos et al., Proc. Natl. Acad. Sci. U.S.A. 89, 7620 (1992 . 22. V. Manetto et al., Neurology 42, 312 (1992) ; P. Gambetti, P. Parchi, R. B. Petersen, S. G. Chen, E. Lugaresi, Brain Pathol. 5, 43 (1995) . 23. R. Hecker et al., Genes Dev. 6, 1213 Callahan, ibid. 72, 293 (1991) . 27. M. Scott, S. J. DeArmond, S. B. Prusiner, unpublished data. 28. R. A. Bessen and R. F. Marsh, J. Gen. Virol. 73, 329 (1992); J. Virol. 68, 7859 (1994) . 29. C. B. Anfinsen, Science 181, 223 (1973) . 30. Homogenates (10%, w/v) of human or mouse brain were prepared by repeated extrusion through an 18-gauge syringe needle followed by a 22-gauge needle in phosphate-buffered saline lacking calcium and magnesium ions. For immunoblot analysis, samples were adjusted to 0.5% NP-40 and 0.5% sodium deoxycholate, and samples were digested with proteinase K (PK) (100 g/ml) for 1 hour at 37°C. Digestion was terminated by the addition of phenylmethylsufonylfluoride (2 mM final concentration) and boiling in electrophoresis sample buffer (3% SDS, 62.5 mM tris, pH 6.8). For deglycosylation, the PK-treated samples were digested for 2 hours with recombinant PNGase F (New England Biolabs) as specified by the supplier, precipitated with four volumes of methanol at Ϫ20°C, and resuspended in electrophoresis sample buffer. 31. R. J. Kascsak et al., J. Virol. 61, 3688 (1987) . 32. T. Muramoto, T. Kitamoto, J. Tateishi, I. Goto, Am. J. Pathol. 140, 1411 . 33. G. C. Telling et al., Genes Dev. 10, 1736 Nitric oxide (NO) and a broad spectrum of hormones, drugs, and toxins raise intracellular cGMP concentrations and thereby regulate a great variety of functions, including smooth muscle relaxation, neuronal excitability, and epithelial electrolyte transport (1) . Depending on the tissue, the increase in cGMP concentrations leads to the activation of different receptors, such as cyclic nucleotide phospodiesterases, cGMPregulated ion channels, and cGK (2) . Although the major effects of cGMP have been attributed to the activation of cGK, its physiological role is still controversial (2, 3) . It has been suggested that cGMP effects are mediated in some cell types by crossactivation of adenosine 3Ј,5Ј-monophosphate (cAMP) kinase (cAK) (3), which shares high homology in the cyclic nucleotide binding domains with the cGKs (4). The identification of the physiological mediator of cGMP is further complicated by the existence of two forms of cGK, type I and type II, which are encoded by distinct genes (5) . Smooth muscle, platelets, and cerebellum contain high concentrations of the type I cGK, whereas cGKII is highly concentrated in brain, lung, and intestinal mucosa (5, 6) . The function of cGKII is not well understood, although there is evidence that it mediates intestinal secretion of water and electrolyte induced by the E. coli toxin STa and the intestinal peptide guanylin (7). To investigate the physiological roles of cGKII, we generated mice carrying a null mutation of the cGKII gene (cGKII Ϫ/Ϫ mice) (8) . The enzyme structure and the targeting vector are shown in Fig. 1A . The deletion of the cGKII gene was confirmed by Northern (RNA) blotting (Fig. 1C) , reverse transcriptase-polymerase chain reaction (RT-PCR) (Fig. 1D) , and immunoblotting of intestinal, brain, and lung extracts (Fig.  1E) . Assays of jejunal homogenates for cGMP-stimulated phosphotransferase activity (9) confirmed that there was no residual cGKII activity in the mutant mice (Fig. 1G) . A deficiency of cGKII had no effect on the integrity of the intestinal cGMP pathway proximal to the kinase, as assayed by STastimulated guanylyl cyclase activity (Fig.  1G ). Immunoblot analysis indicated that expression of cGKI or the catalytic subunits of cAK was not affected by the absence of cGKII (Fig. 1, E and F) . Heterozygous matings of outbred and inbred mice produced viable pups (n ϭ 202) with the expected Mendelian frequency. These mice were also fertile as adults, suggesting that embryonic and fetal development of cGKII-deficient animals was not impaired.
We first tested the effects of cGKII deficiency on intestinal fluid secretion. The cAMP-and cGMP-signaling cascades are key regulators of intestinal chloride and water secretion through the cystic fibrosis transmembrane conductance regulator (CFTR) (3, 7) . Some studies have suggested that cGKII mediates the pathophysiological effects of E. coli STa (6, 7) , a heatstable enterotoxin that increases cellular cGMP concentrations and induces diarrhea (10) , whereas other studies have implicated cross-activation of cAK in these effects (3) . We studied electrogenic anion secretion in small intestine and caecum (11) by measuring the short-circuit current (I sc ) of mucosal (A) Epithelial electrolyte transport in stripped mucosa sections from the jejunum of wild-type (s) and cGKII-null (F) mice. The transepithelial electric potential difference was measured in Ussing chamber setups, and the short-circuit current (I sc ) was calculated as in (12) . The mucosa sections were treated sequentially with 1 M tetrodotoxin (a), 100 nM STa (b), 0.2 mM 8-BrcGMP (c), 1 mM 8-BrcGMP (d), and 1 mM 8-BrcAMP (e). Thereafter the tissues were exposed to 100 M bumetanide (f ), which blocks basolateral cotransport of Na ϩ , K ϩ , and 2Cl Ϫ , and to 500 M ouabain (g), which blocks Na segments (12) treated with STa, cGMP, and cAMP ( Fig. 2A) . The I sc of the mouse small intestine is mainly due to CFTRregulated Cl Ϫ conductance (13) . As expected, treatment of mucosal segments from normal mice with 100 nM STa led to a significant stimulation of I sc that was further increased by the addition of 0.2 mM and 1 mM 8-bromo-cGMP (8-BrcGMP) ( Fig. 2A) . Maximum stimulation of I sc was obtained by superfusion with 1 mM 8-bromo-cAMP . In contrast to these findings, cGKII-null mice showed only a marginal stimulation of I sc after STa treatment that was not increased by the addition of 0.2 mM or 1 mM 8-BrcGMP. Jejunal mucosa of cGKII-deficient mice responded normally to 1 mM 8-BrcAMP, demonstrating that the absence of cGKII selectively disrupts the STa-cGMP but not the cAMP pathway.
To evaluate the pathophysiological significance of these observations, we induced secretory diarrhea in newborn mice by intragastric injection of STa (14) . Fluid secretion into the intestine of the live animal can be quantified by determining the ratio of gut weight to carcass weight (g/c ratio): g/c ratios greater than 0.083 indicate a diarrheal response, whereas ratios less than 0.074 indicate no response to STa (10) . In the cGKII ϩ/ϩ and cGKII ϩ/Ϫ mice, STa induced the accumulation of clear fluid in the intestine, and the g/c ratio increased to 0.092 Ϯ 0.006 (n ϭ 5) and to 0.088 Ϯ 0.004 (n ϭ 5), respectively (Fig. 2B) contrast, cGKII Ϫ/Ϫ mice showed no accumulation of fluid in the intestine after STa treatment. This lack of response to STa was reflected by a g/c ratio of 0.062 Ϯ 0.002 (n ϭ 5) (Fig. 2B) . However, inactivation of cGKII did not affect the secretory response to agents that raise intestinal cAMP concentrations such as cholera toxin (CT) (Fig.  2B) .
As the cGKII Ϫ/Ϫ mice grew, dwarfism, short limbs (micromelia), and cranial abnormalities became apparent. The difference in body length between cGKII ϩ/ϩ and cGKII Ϫ/Ϫ mice (15) increased until it reached a constant level at 8 to 10 weeks (Fig. 3A) . At this age the mutant mice were 16% shorter and weighed 14% less than their cGKII ϩ/ϩ littermates. X-ray analysis (Fig. 3B) and staining of skeletons with alizarin-red (16) revealed a 23 to 30% reduction in the length of the long bones and vertebrae (Fig. 3C) . In contrast, the size and weight of the organs within the shortened trunk of cGKII-null mice were normal (16) , resulting in a distended abdomen (Fig. 3B) . The serum electrolyte levels, bone density, and total body fat (16) of the cGKII-null mice were also normal. These findings, together with the detection of cGKII mRNA in the chondrocytes of the developing bone by in situ hybridization (Fig. 3G) , suggest that cGKII has a direct role in bone growth.
The normal development of membranous bones like the clavicles (Fig. 3C) and bones of the cranial vault but not of the base of the cranium suggested that the cGKII-null mutation specifically inhibited endochondral but not membranous ossification. During endochondral ossification, bone is deposited on a calcified cartilage matrix that is produced by the growth plate (17) . The growth plate is responsible for linear skeletal growth and is characterized by the transition from resting to proliferative to hypertrophic chondrocytes, typically in orderly columnar arrays (17) (Figs. 3D  and 4A ).
To determine whether growth plate chondrocytes express cGK, we did immunohistochemical stainings with antibodies specific for the two cGK enzymes. Immunohistochemistry for cGKII provided specific staining of a population of chondrocytes located at the border between the proliferative and hypertrophic zone (Fig.  3E) . In addition, a weak staining was observed in early proliferative and resting chondrocytes (Fig. 3E) . The staining was not present in the cGKII Ϫ/Ϫ animals and also could be competed with purified recombinant cGKII (16) . We could also detect cGKI expression in the growth plate that was confined to the hypertrophic zone (Fig. 3F) . Preincubation of the cGKI-specific antibody with purified cGKI protein (20 g/ml) abolished the signal. The cGKI expression pattern and density were not affected by the absence of cGKII (16) . In situ hybridization studies (Fig. 3, G and H) confirmed the predominant expression of cGKII in the late proliferative and early hypertrophic chondrocytes.
Histological examination of long bones did not reveal substantial abnormalities in newborn cGKII Ϫ/Ϫ mice. Starting at the first week postpartum, the cGKII Ϫ/Ϫ mice developed severe defects in the axial organization of the growth plate, which were most prominent at 3 to 4 weeks of age (Fig. 4B) . At this age, cGKII-null mice showed significant changes in growth plate histology consisting of irregular and broadened hypertrophic zones with patches of nonhypertrophic cells intermingled with hypertrophic chondrocytes, even close to the area of vascular invasion. These cells were identified as proliferative chondrocytes by [ 3 H]thymidine incorporation (Fig. 4, C and D) . In contrast to the wild-type mice (Fig. 4A) , the cGKII-null mice showed no clear separation between the proliferative and hypertrophic zone (Fig.  4B) . At 6 to 8 weeks of age, cGKII ϩ/ϩ and cGKII Ϫ/Ϫ growth plates became smaller, but the mutants showed wedge-shaped columns of mixed hypertrophic and proliferative chondrocytes protruding into the trabecular bone (16) .
To exclude the possibility that malabsorption or imbalances in hormones or growth factors were responsible for the retarded growth of the skeleton, we transplanted (15) mutant and normal long bones into normal mice. Whereas the length of normal long bones increased 23 Ϯ 4% (n ϭ 6), the mutant bones grew only marginally when transplanted into normal mice (Fig. 4E) . Furthermore, long bones explanted from wild-type mice developed normally when implanted into cGKII-deficient mice (Fig. 4E) . These results suggest that the growth defect in the mutant mice is not due to a general metabolic disturbance.
The phenotype of the cGKII-deficient mice point to a central role for cGKII in diverse physiological processes. The identification of the pathway that mediates intestinal fluid secretion by E. coli STa has potential medical implications, because STa causes traveller's diarrhea and about 50% of infant mortality in developing countries (10) . Finally the unexpected link between cGKII and bone growth may be an important step for understanding the pathophysiology for a range of bone and joint diseases.
